Genetic testing for thrombophilia mutations

Seminars in Thrombosis and Hemostasis

Volumn 31, Issue 1, 2005, Pages 33-38

  Hertzberg, Mark S ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

DNA; Genetic testing; PCR; Thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; DNA; PROTHROMBIN;

ANTICOAGULATION; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA MICROARRAY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PROCEDURES; GENETIC SCREENING; HUMAN; LABORATORY DIAGNOSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; REVIEW; THROMBOPHILIA; VEIN THROMBOSIS;

ANTITHROMBINS; DNA; DNA MUTATIONAL ANALYSIS; FACTOR V; GENETIC SCREENING; GENETIC TECHNIQUES; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROTEIN C; PROTEIN S; PROTHROMBIN; RISK FACTORS; THROMBOPHILIA;

EID: 13844315228     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-863803     Document Type: Review

References (52)

1. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-1173
2. Bertina R. Molecular risk factors for thrombosis. Thromb Haemost 1999;82:601-609
3. De Stefano V, Finazzi G, Manucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996;87:3531-3544
4. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001;344:1222-1231
5. Lane DA, Bayston T, Olds RJ, et al. Antithrombin mutation database; 2nd (1997) update. For the plasma coagulation inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997;77:197-211
6. Reitsma PH, Bernardi F, Doig RG, et al. Protein C deficiency: a database of mutations, 1995 update. On behalf of the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1995;73:876-889
7. Gandrille S, Borgel D, Sala N, et al. Protein S deficiency: a database of mutations - summary of the first update. Thromb Haemost 2000;84:918
8. Zivelin A, Grittin JH, Xu X, et al. A single genetic defect for a common Caucasian risk factor for venous thrombosis. Blood 1997;89:397-402
9. Zivelin A, Rosenberg N, Faier S, et al. A single genetic origin for the common prothrombotic G20210 polymorphism in the prothrombin gene. Blood 1998;92:1119-1124
10. Rees DC, Cox M, Clegg JB. World distributions of factor V Leiden. Lancet 1995;346:1133-1134
11. Rosendaal FR, Doggen CJM, Zivelin A, et al. Geographical distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998;79:706-708
12. Manucci PM, Tripodi A, Botasso B, et al. Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb Haemost 1992;67:200-202
13. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67
14. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995;270:4053-4057
15. Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995;85:3405-3411
16. Koster T, Rosendaal FR, De Ronde H, et al. Venous thrombosis due to a poor anticoagulant response to activated protein C. Leiden Thrombophilia Study. Lancet; 1993;342:1503-1506
17. Press RD, Bauer KA, Kukovich JL, Heit JA. Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 2002;126:1304-1318
18. Middledorp S, Meinardi JR, Koopman MM, et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001;135:322-327
19. Simioni P, Tormene D, Prandoni P, et al. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood 2002;99:1938-1942
20. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma pro-thrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703
21. Gehring NH, Frede U, Neu-Yilik G, et al. Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet 2001;28:389-392
22. Butenas S, van't VeerC, Mann KG. "Normal" thrombin generation. Blood 1999;94:2169-2178
23. Arruda VR, Annichino-Bizzacchi JM, Gonclaves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20210) in venous thrombosis and arterial disease. Thromb Haemost 1997;78:1430-1433
24. McGlennen RC, Key NS. Clinical and laboratory management of the prothrombin G20210A mutation. Arch Pathol Lab Med 2002;126:1319-1325
25. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-113
26. Franco RF, Araujo AG, Guerreiro JF, Elion J, Zago MA. Analysis of the 677 C → T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups. Thromb Haemost 1998;79:119-121
27. Key NS, McGlennen RC. Hyperhomocysteinemia and thrombophilia. Arch Pathol Lab Med 2002;126:1367-1375
28. Kluijtmans LA, den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998;79:254-258
29. 306 → Thr) associated with resistance to acquired protein C. Blood 1998;91:1140-1144
30. Faioni EM, Franchi F, Bucciarelli P, et al. Co-inheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). Blood 1999;94:3062-3066
31. Bernardi F, Faioni EM, Castoldi E, et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1998;90:1552-1557
32. Castaman G, Faioni EM, Tosetto A, Bernardi F. The factor V HR2 haplotype and the risk of venous thrombosis: a meta-analysis. Haematologica 2003;88:1182-1189
33. Faioni EM, Castaman G, Asti D, et al. Association of factor V deficiency with factor V HR2. Haematologica 2004;89:195-200
34. Tripodi A, Manucci PM. Laboratory investigation of thrombophilia. Clin Chem 2001;47:1597-1606
35. Pecheniuk NM, Walsh TP, Marsh NA. DNA technology for the detection of common genetic variants that predispose to thrombophilia. Blood Coagul Fibrinolysis 2000;11:683-700
36. Gomez E, van der Poel SCPAM, Jansen JH, van der Reijden LM, Lowenberg R. Rapid simultaneous screening of factor V Leiden and G20210A prothrombin variant by multiplex polymerase chain reaction on whole blood. Blood 1998;91:2208-2211
37. Muriel G, Christine B, Philippe J, Christophe M, Francois SJ, Patricia AM. An even easier method for one-step detection of both FV Leiden and FII G20210A transition. Blood 1998;92:3478-3479
38. Hezard N, Cornillet P, Droulle C, Gillot L, Potron G, Nguyen P. Factor V Leiden: detection in whole blood by ASA PCR using an additional mismatch in antepenultimate position. Thromb Res 1997;88:59-66
39. Poort SR, Bertina RM, Vos HL. Rapid detection of the prothrombin 20210A variation by allele-specific PCR. Thromb Haemost 1997;78:1157-1158
40. Mitterer M, Lanthaler AJ, Mair W, Giacomuzzi K, Coser P. Simultaneous detection of FV Q506and prothrombin 20210 A variation by allele-specific PCR. Haematologica 1999;84:204-207
41. Van D Locht LTF, Kuypers AWHM, Verbruggen BW, Linssen PCM, Novakova IRO, Mensink EJBM. Semi-automated detection of factor V mutation by allele-specific amplification and capillary electrophoresis. Thromb Haemost 1995;74:1276-1279
42. Margaglione M, D'Andrea G, Capucci G, et al. Detection of the factor V Leiden using SSCP. Thromb Haemost 1996;76:814-815
43. Hezard N, Cornillet P, Vallade P, Nguyen P. Detection of factor V Leiden using ASO (allele specific oligonucleotide). Thromb Haemost 1997;78:1296
44. Zotz RB, Marhun-Debowski B, Sharf RE. Mutation in the gene coding for coagulation factor V and resistance to activated protein C: detection of the genetic mutation by oligonucleotide ligation assay using a semi-automated system. Thromb Haemost 1996;76:53-55
45. Pecheniuk NM, Marsh NA, Walsh TP. Multiple analysis of three common genetic alterations associated with thrombophilia. Blood Coagul Fibrinolysis 2000;11:183-189
46. Ameziane N, Lamotte M, Lamoril J, et al. Combined factor V Leiden (G1691A) and prothrombin (G20210A) genotyping by multiplex real-time polymerase chain reaction using fluorescent resonance energy transfer hybridization probes on the Rotor-Gene 2000. Blood Coagul Fibrinolysis 2003;14:421-424
47. Cooper PC, Cooper SM, Smith JM, Kitchen S, Makris M. Evaluation of the Roche LightCycler: a simple and rapid method for direct detection of factor V Leiden and prothrombin G20210A genotypes from blood samples without the need for DNA extraction. Blood Coagul Fibrinolysis 2003;14:499-503
48. Schrijver I, Lay MJ, Zehnder JL. Diagnostic single nucleotide polymorphism analysis of factor V Leiden and prothrombin 20210G>A. A comparison of the Nanogen Electronic Microarray with restriction enzyme digestion and the Roche LightCycler. Am J Clin Pathol 2003;119:490-496
49. Green D. Genetic hypercoagulability: screening should be an informed choice. Blood 2001;98:20
50. Machin SJ. Pros and cons of thrombophilia testing: cons. J Thromb Haemost 2003;1:412-413
51. Manucci PM. Genetic hypercoagulability: prevention suggests testing family members. Blood 2001;98:21-22
52. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003;362:523-526